Page 2 - ஒன்றுபட்டது கிஂக்டம் எதிர்கால நிதி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund

Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNorthern irelandCity ofFrazer hallNeuroscienceronan cunninghamCitigate dewe rogersondavidRuth mckernanBill gatesEli lillyRonan cunninghamOtsuka astexMelanie leeNathaniel dahanSeed fundSv health investors

Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund

Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNorthern irelandCity ofFrazer hallRuth mckernanBill gatesEli lillyRonan cunninghamOtsuka astexMelanie leeNathaniel dahanCitigate dewe rogersonSeed fundSv health investorsUnited kingdom government department of health

Investors Back Spinout s Therapy Developments for SNHL Labmate Online

May 01 2021 Read 4 Times University of Sheffield spinout company, Rinri Therapeutics, has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund, to support the development of its novel stem cell therapy to treat sensorineural hearing loss (SNHL). The company’s underlying technology is based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield. It seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear. SNHL happens when there is damage to the hair cells in the cochlea and/or to the auditory nerve. There are currently no pharmacological treatments available for SNHL despite the increasing number of patients that suffer from this condition globally.

United kingdomMarcelo rivoltaSimon chandlerFrank kalkbrennerUnited kingdom government future fundBoehringer ingelheim venture fundUnited kingdom future fundUniversity of sheffieldRinri therapeuticsProfessor marcelo rivoltaUnited kingdom futureGlobal headஒன்றுபட்டது கிஂக்டம்சிமோன் சாண்ட்லர்ஒன்றுபட்டது கிஂக்டம் அரசு எதிர்கால நிதிபோஹெரிங்கர் இஂகல்‌ஹைம் துணிகர நிதி

Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund

Search jobs Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. The proceeds will support the development of the Company’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL). Rinri’s underlying technology, based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield from where the company was spun out, seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear. SNHL happens when there is damage to the hair cells in the cochlear and/or the auditory nerve. There are currently no pharmacological treatments available for SNHL despite t

United kingdomMarcelo rivoltaSimon chandlerUnited kingdom government future fundBoehringer ingelheim venture fundUnited kingdom future fundUniversity of sheffieldRinri therapeuticsUnited kingdom government futureProfessor marcelo rivoltaUnited kingdom futureஒன்றுபட்டது கிஂக்டம்சிமோன் சாண்ட்லர்ஒன்றுபட்டது கிஂக்டம் அரசு எதிர்கால நிதிபோஹெரிங்கர் இஂகல்‌ஹைம் துணிகர நிதிஒன்றுபட்டது கிஂக்டம் எதிர்கால நிதி

Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss

Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss News provided by Share this article Share this article SHEFFIELD, England, April 20, 2021 /PRNewswire/ Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of £10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. The proceeds will support the development of the Company s novel stem cell therapy to reverse sensorineural hearing loss (SNHL). Rinri s underlying technology, based on innovative research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield from where the company was spun out, seeks to reverse SNHL through the repair of the damaged cytoarchitecture in the inner ear. SNHL happens when there is damage to the hai

United kingdomFrazer hallMarcelo rivoltaSimon chandlerFrank kalkbrennerSylvie berrebiCitigate dewe rogersonBritish business bankUnited kingdom government future fundBoehringer ingelheim venture fundUnited kingdom future fundUniversity of sheffieldRinri therapeuticsUnited kingdom government futureProfessor marcelo rivoltaUnited kingdom future